Recent News

• 06.29.2025 - 2025 Annual Meeting of Shareholders
• 06.29.2025 - 2025 Annual Meeting of Shareholders
• 05.30.2025 - BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
• 05.27.2025 - BioLineRx to Report First Quarter 2025 Results on May 27, 2025
• 05.27.2025 - BioLineRx to Report First Quarter 2025 Results on May 27, 2025
• 05.27.2025 - BioLineRx to Report First Quarter 2025 Results on May 27, 2025
• 05.27.2025 - BioLineRx to Report First Quarter 2025 Results on May 27, 2025
• 05.27.2025 - BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.20.2025 - BioLineRx to Report First Quarter 2025 Results on May 27, 2025
• 03.31.2025 - BioLineRx to Report 2024 Annual Results on March 31, 2025

Recent Filings

• 05.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.23.2025 - EX-99.1 EX-99.1
• 04.11.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.31.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.31.2025 - EX-99.1 EX-99.1
• 03.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]